SAN RAMON, Calif., Oct. 9, 2020 /PRNewswire/ -- CooperVision is
reporting the latest findings from its landmark MiSight®
1 day clinical study, providing new insights about myopia
management and the proven efficacy of the specially designed
contact lens. Among many powerful outcomes are that nearly one in
four children's eyes originally fit with MiSight® 1 day
remain stable for myopia after six years.1
Paul Chamberlain, CooperVision's
Director of Research Programs, will share additional details this
evening, Friday, October 9 at
8:45 pm EST, during a paper
presentation1 at the American Academy of Optometry's
virtual annual meeting.
"Evaluating children who were prescribed MiSight® 1
day at the study's initiation, 23% of eyes after year six displayed
a total refractive change of less than -0.25D (spherical
equivalent), which could be considered clinically stable," said
Chamberlain.1 "There is now even more reason to
recognize the substantial capability of this unique dual-focus
contact lens."
The newest findings also suggest that while intervention at an
early age is optimal with MiSight® 1 day, commencing
treatment at an older age could similarly slow the rate of myopia
progression.1 The original control group was refit
into the dual-focus lens in year four. Comparing this population to
the children fit with MiSight® 1 day at initiation,
there have been similar rates of myopia progression and axial
length growth in the subsequent three years of
assessment.1
Six-year results continue to demonstrate excellent safety
profile, wearing time, and visual acuity for children in daily
disposable contact lenses over 653 wearing
years.1 No other prospective randomized controlled
study has offered conclusive data for such a high degree of
continued efficacy in myopia management using a soft contact lens
over a similar time span.
Myopia—also known as nearsightedness or short-sightedness—is
projected to affect the vision and increase risks to ocular health
of approximately five billion people by 2050, more than doubling
today's numbers.2 Myopic progression has been linked to
sight-threatening conditions later in life such as cataracts,
retinal detachment, glaucoma3 and myopic
maculopathy.4
Additional CooperVision Myopia Management Research at Academy
2020
Age is further explored in an Academy virtual poster session now
underway. Effects of Age on Myopia Progression with Dual-Focus
and Single Vision Daily Disposable Contact Lenses (Arumugam et
al., 2020) concludes that observed treatment effects in myopia
management clinical trials may be dependent on the age of the
subjects and study duration. Annual axial elongation rates were
slowed by wearing MiSight® 1 day during every year for
ages 8-14 and myopia progression significantly slowed for ages
8-13. These results also emphasize the importance of early
intervention to slow pathological growth during years of more rapid
progression. Early intervention also allows an accumulating
management effect over more years, resulting in greater total
outcomes.
CooperVision MiSight® 1 day is the first and only
soft contact lens the U.S. Food and Drug Administration has
approved* for slowing the progression of myopia in children, who at
initiation of treatment are 8-12 years of age.[5] It is the
centerpiece of the company's Brilliant Futures™ Myopia Management
Program, in which more than 1,000 U.S. ECPs are now certified.
Versions of this comprehensive program are presently being
introduced in other countries, including the United Kingdom, Canada, Spain
and Portugal.
Reporting six-year data at Academy 2020 and ongoing research are
part of a series of far-reaching initiatives by CooperVision to
help educate eye care and healthcare professionals about advances
in myopia management, including widespread conference
participation, study support, clinical training events and
more.
"As far as we have come with myopia management in recent years,
there remains much to be done, including deeper partnerships with
the optometry, ophthalmology and public health communities," said
James Gardner, Vice President for
Global Myopia Management at CooperVision. "We're a steadfast
advocate for evidence-based advancements. I believe the six-year
results will further our scientific understanding of myopia
progression and increase clinical enthusiasm for proven management
options such as MiSight® 1 day."
* Indications
for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact
lenses for daily wear are indicated for the correction of myopic
ametropia and for slowing the progression of myopia in children
with non-diseased eyes, who at the initiation of treatment are 8-12
years of age and have a refraction of -0.75 to -4.00
diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism.
The lens is to be discarded after each removal.
|
1 Chamberlain P, Logan N, Jones D,
Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a
dual-focus myopia control 1 day soft contact lens: 6-year results
(2020 American Academy of Optometry Annual Meeting).
|
2 Holden et al, - Global Prevalence
of myopia and high myopia and temporal trends from 2000 through
2050. Ophthalmology 2016. 123(5):1036-1042
|
3 What You Should Know if Your Child
is Nearsighted (Infographic). Retrieved October 29, 2019 from:
https://www.allaboutvision.com/parents/myopia-facts-infographic.htm
|
4 Macular Society. Myopia,
Pathological Myopia and Myopic Macular Degeneration. Retrieved
October 29, 2019 from:
https://www.macularsociety.org/sites/default/files/resource/Macular%20Society%20Factsheet%20-%20Myopic%20Macular%20Degeneration%202017%20-%20ACCESS.pdf
|
5 Chamberlain P, et al. A 3-year
randomized clinical trial of MiSight® lenses for myopia control.
Optom Vis Sci. 2019; 96(8):556-567. Compared to a single vision 1
day lens over a 3 year period
|
About CooperVision
CooperVision, a division of
CooperCompanies (NYSE:COO), is one of the world's leading
manufacturers of soft contact lenses. The Company produces a full
array of daily disposable, two-week and monthly contact lenses, all
featuring advanced materials and optics. CooperVision has a strong
heritage of solving the toughest vision challenges such as
astigmatism, presbyopia and childhood myopia; and offers the most
complete collection of spherical, toric and multifocal products
available. Through a combination of innovative products and focused
practitioner support, the company brings a refreshing perspective
to the marketplace, creating real advantages for customers and
wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies ("Cooper") is a
global medical device company publicly traded on the NYSE
(NYSE:COO). Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of
more than 12,000 with products sold in over 100 countries. For more
information, please visit www.coopercos.com.
Media Contact
Mike
McDougall, APR, Fellow PRSA, McDougall Communications
mike@mcdougallpr.com or +1-585-434-2150
View original content to download
multimedia:http://www.prnewswire.com/news-releases/coopervision-presents-six-year-data-from-misight-1-day-study-23-of-eyes-showed-no-additional-myopia-progression-after-fitting-301148099.html
SOURCE CooperVision